Reviewof Operations BUSINESSOVERVIEW INOVIQ Ltd (ASX:IIQ) (INOVIQ®) is developing and commercialising next-generation exosome capture tools and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the EXO‐ NET® pan‐ exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. INOVIQ’s cancer diagnostic pipeline includes blood tests in development for the earlier detection and monitoring of ovarian, breast and other cancers. HIGHLIGHTS INOVIQ advanced its innovative exosome-based and diagnostic products and pipeline towards key development and commercialisation milestones during the financial year, including: Commercial – Multiple positive evaluations of EXO-NET pan-exosome capture tool were successfully completed by key Australian and US-based research organisations, with data provided to the company for use in its marketing materials – Percorso Life Sciences engaged to provide contract sales and logistics services in the USA. This agreement is a key step toward driving EXO-NET research tool sales in the largest geographic market segment for exosome research products – Plans progressed to transfer, scale-up and manufacture EXO-NET under cGMP conditions at the Company’s Melbourne facility to meet expected demand for EXO-NET research tools and enable future builds of custom-designed products – Master Manufacturing Agreement executed withMP Biomedicals, a global supplier of life science and diagnostic products, for the contract manufacture of INOVIQ’s proprietary SubB2Mprotein to cGMP standard – Multiple patents granted protecting the Company’s NETs, SubB2M, BARD1 and hTERT technologies and products We are pleased to present the Group’s Annual Report for the financial year ended 30 June 2022 and provide an update on further strategic and operational progress since year end. 6 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3